Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.

Triple-negative breast cancer (TNBC) is an aggressive, highly recurrent breast cancer subtype, affecting approximately one-fifth of all breast cancer patients. Subpopulations of treatment-resistant cancer stem cells within the tumors are considered to contribute to disease recurrence. A potential dr...

Full description

Bibliographic Details
Main Authors: Marisa Simon, Fahmi Mesmar, Luisa Helguero, Cecilia Williams
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5325553?pdf=render
_version_ 1818477176570249216
author Marisa Simon
Fahmi Mesmar
Luisa Helguero
Cecilia Williams
author_facet Marisa Simon
Fahmi Mesmar
Luisa Helguero
Cecilia Williams
author_sort Marisa Simon
collection DOAJ
description Triple-negative breast cancer (TNBC) is an aggressive, highly recurrent breast cancer subtype, affecting approximately one-fifth of all breast cancer patients. Subpopulations of treatment-resistant cancer stem cells within the tumors are considered to contribute to disease recurrence. A potential druggable target for such cells is the maternal embryonic leucine-zipper kinase (MELK). MELK expression is upregulated in mammary stem cells and in undifferentiated cancers, where it correlates with poor prognosis and potentially mediates treatment resistance. Several MELK inhibitors have been developed, of which one, OTSSP167, is currently in clinical trials. In order to better understand how MELK and its inhibition influence TNBC, we verified its anti-proliferative and apoptotic effects in claudin-low TNBC cell lines MDA-MB-231 and SUM-159 using MTS assays and/or trypan blue viability assays together with analysis of PARP cleavage. Then, using microarrays, we explored which genes were affected by OTSSP167. We demonstrate that different sets of genes are regulated in MDA-MB-231 and SUM-159, but in both cell lines genes involved in cell cycle, mitosis and protein metabolism and folding were regulated. We identified p53 (TP53) as a potential upstream regulator of the regulated genes. Using western blot we found that OTSSP167 downregulates mutant p53 in all tested TNBC cell lines (MDA-MB-231, SUM-159, and BT-549), but upregulates wild-type p53 in the luminal A subtype MCF-7 cell line. We propose that OTSSP167 might have context-dependent or off-target effects, but that one consistent mechanism of action could involve the destabilization of mutant p53.
first_indexed 2024-12-10T09:34:48Z
format Article
id doaj.art-64689cf839f6473ea389e18b3badd0d3
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T09:34:48Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-64689cf839f6473ea389e18b3badd0d32022-12-22T01:54:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017283210.1371/journal.pone.0172832Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.Marisa SimonFahmi MesmarLuisa HelgueroCecilia WilliamsTriple-negative breast cancer (TNBC) is an aggressive, highly recurrent breast cancer subtype, affecting approximately one-fifth of all breast cancer patients. Subpopulations of treatment-resistant cancer stem cells within the tumors are considered to contribute to disease recurrence. A potential druggable target for such cells is the maternal embryonic leucine-zipper kinase (MELK). MELK expression is upregulated in mammary stem cells and in undifferentiated cancers, where it correlates with poor prognosis and potentially mediates treatment resistance. Several MELK inhibitors have been developed, of which one, OTSSP167, is currently in clinical trials. In order to better understand how MELK and its inhibition influence TNBC, we verified its anti-proliferative and apoptotic effects in claudin-low TNBC cell lines MDA-MB-231 and SUM-159 using MTS assays and/or trypan blue viability assays together with analysis of PARP cleavage. Then, using microarrays, we explored which genes were affected by OTSSP167. We demonstrate that different sets of genes are regulated in MDA-MB-231 and SUM-159, but in both cell lines genes involved in cell cycle, mitosis and protein metabolism and folding were regulated. We identified p53 (TP53) as a potential upstream regulator of the regulated genes. Using western blot we found that OTSSP167 downregulates mutant p53 in all tested TNBC cell lines (MDA-MB-231, SUM-159, and BT-549), but upregulates wild-type p53 in the luminal A subtype MCF-7 cell line. We propose that OTSSP167 might have context-dependent or off-target effects, but that one consistent mechanism of action could involve the destabilization of mutant p53.http://europepmc.org/articles/PMC5325553?pdf=render
spellingShingle Marisa Simon
Fahmi Mesmar
Luisa Helguero
Cecilia Williams
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
PLoS ONE
title Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
title_full Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
title_fullStr Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
title_full_unstemmed Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
title_short Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
title_sort genome wide effects of melk inhibitor in triple negative breast cancer cells indicate context dependent response with p53 as a key determinant
url http://europepmc.org/articles/PMC5325553?pdf=render
work_keys_str_mv AT marisasimon genomewideeffectsofmelkinhibitorintriplenegativebreastcancercellsindicatecontextdependentresponsewithp53asakeydeterminant
AT fahmimesmar genomewideeffectsofmelkinhibitorintriplenegativebreastcancercellsindicatecontextdependentresponsewithp53asakeydeterminant
AT luisahelguero genomewideeffectsofmelkinhibitorintriplenegativebreastcancercellsindicatecontextdependentresponsewithp53asakeydeterminant
AT ceciliawilliams genomewideeffectsofmelkinhibitorintriplenegativebreastcancercellsindicatecontextdependentresponsewithp53asakeydeterminant